Kengreal Injection, Powder, Lyophilized, For Solution
Product Images NDC 10122-620

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Kengreal (NDC 10122-620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chiesi Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Bleeding Results In The Champion Phoenix Studya (all Non-cabg Related) (Kengreal 1)

A forest plot comparing the effectiveness of KENGREAL (cangrelor) and clopidogrel across various patient subgroups. It displays odds ratios (OR) with 95% confidence intervals (CI) for different factors including age, gender, race, weight, patient presentation, prior TIA/stroke, and diabetes status. The plot visually indicates the comparative outcomes favoring either KENGREAL or clopidogrel.*

FDA Label Image

Chemical Structure (Kengreal 2)

Chemical structure of cangrelor depicted with detailed atomic bonds and molecular groups, including phosphate, sugar, and purine components as shown in the image.*

FDA Label Image

Figure 2: Cangrelor Pd Characteristics (Kengreal 3)

A line graph showing pharmacokinetic (PK) and pharmacodynamic (PD) profiles over time after administration of cangrelor injection. The x-axis represents time in minutes (0 to 160), the left y-axis shows concentration in ng/mL, and the right y-axis shows percentage platelet aggregation (impedance). The PK line plots plasma concentration, and the PD line plots platelet activity, with data points and error bars. The graph includes annotations for dosing (bolus 30 mcg/kg, infusion 4 mcg/kg/min) and a recovery time of about 60 minutes.*

FDA Label Image

Figure 3: Inhibition (mean) Of 20 µm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Cangrelor 30 Mcg/kg Bolus And 120-minute 4 Mcg/kg Infusion With Transition To Other Oral P2y12 Platelet Inhibitors. (Kengreal 4)

A line graph depicting the % IPA over time (hours) during cangrelor infusion and subsequent administration of clopidogrel, prasugrel, or ticagrelor. The graph shows different profiles for cangrelor switched to each of the three drugs from 0 to 6 hours, illustrating changes in IPA response.*

FDA Label Image

Figure 4: Champion Phoenix Study: Primary Efficacy Endpoint By Subgroup (mitt Populationa) (Kengreal 5)

A forest plot comparing the efficacy of Kengreal (cangrelor) injection 50 mg/1 versus clopidogrel across various patient subgroups. The plot shows odds ratios with 95% confidence intervals for outcomes, including age, gender, race, weight, patient presentation, prior treatments, and diabetes status. The horizontal axis indicates whether Kengreal or clopidogrel is favored.*

FDA Label Image

Kengreal (cangrelor) For Injection 50 mg Vial Carton (Kengreal 6)

Packaging label for KENGREAL (cangrelor) 50 mg per vial injection, powder, lyophilized for solution. The label shows a carton designed for 10 single-use vials intended for intravenous use. It includes storage instructions, reconstitution directions, barcodes, and the Chiesi USA, Inc. logo as the labeler.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.